<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054895</url>
  </required_header>
  <id_info>
    <org_study_id>LEVEL-AT</org_study_id>
    <nct_id>NCT04054895</nct_id>
  </id_info>
  <brief_title>LEft VEntricuLar Activation Time Shortening With Physiological Pacing vs Biventricular Resynchronization Therapy</brief_title>
  <acronym>LEVEL-AT</acronym>
  <official_title>LEft VEntricuLar Activation Time Shortening With Physiological Pacing vs Biventricular Resynchronization Therapy: a Randomized Study (LEVEL-AT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josep Lluis Mont Girbau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LEVEL-AT Trial (LEft VEntricuLar Activation Time Shortening with Physiological Pacing vs&#xD;
      Biventricular Resynchronization therapy: a randomized study) is a non-inferiority study that&#xD;
      aims to determine if physiological pacing could decrease the left ventricular activation time&#xD;
      compared with biventricular therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date studies have showed that physiological pacing could get similar clinical and&#xD;
      echocardiographic response to that obtained with biventricular therapy. Activation time&#xD;
      shortening with permanent physiological pacing has not been studied.&#xD;
&#xD;
      This study will randomize 70 patients to a strategy of: biventricular pacing versus&#xD;
      physiological pacing.&#xD;
&#xD;
      LEVEL-AT study will analyze the following parameters in the 2 groups: shortening of the QRS,&#xD;
      activation time with electrocardiographic imaging, echocardiographic asynchrony and&#xD;
      ventricular function and clinical parameters (NYHA functional class, mortality and heart&#xD;
      failure hospitalization).&#xD;
&#xD;
      Clinical, electrocardiographic, echocardiographic and electrocardiographic imaging follow-up&#xD;
      will be performed for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, unicentric, simple blind.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The patient will be explained to be randomized to either of the two branches. The type of therapy applied will not be communicated to the patient. The follow-up will be the same in the two branches. During the visits it will not be said which therapy has been applied.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular activation time.</measure>
    <time_frame>45 days</time_frame>
    <description>Left ventricular activation time measured by eletrocardiographic imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QRS duration.</measure>
    <time_frame>Implant, 6 months and 12 months.</time_frame>
    <description>QRS duration (milliseconds) measured with a 12-lead ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular activation time.</measure>
    <time_frame>6 months and 12 months.</time_frame>
    <description>Left ventricular activation time measured by eletrocardiographic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular function.</measure>
    <time_frame>6 months and 12 months.</time_frame>
    <description>Left ventricular ejection fraction measured with Simpson method with echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in end-systolic volume.</measure>
    <time_frame>6 months and 12 months.</time_frame>
    <description>End-systolic volume measured with echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA functional class.</measure>
    <time_frame>6 months and 12 months.</time_frame>
    <description>NYHA functional class I, II, III, IV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to heart failure or mortality (combined endpoint).</measure>
    <time_frame>1 year.</time_frame>
    <description>Hospitalization: patient hospitalization (yes/no) Mortality: mortality (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correction of septal flash</measure>
    <time_frame>15 days</time_frame>
    <description>Correction of septal flash determined with echocardiography (M mode)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Physiological Pacing</condition>
  <condition>Resynchronization Therapy</condition>
  <arm_group>
    <arm_group_label>Physiological pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pacing the his-purkinje system.&#xD;
Crossover to biventricular CRT will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (&gt;3.5V / 1ms); no shortening of QRS (shortening &lt;20%) or failure to meet non-selective HBP criteria [Europace. 2019 Oct 9. doi: 10.1093/europace/euz275].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biventricular resynchronization therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.&#xD;
Crossover from biventricular CRT to physiological pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lead placed in the His-Purkinje system in order to achieve QRS shortening.</intervention_name>
    <description>Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).</description>
    <arm_group_label>Physiological pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lead is placed in a tributary of the coronary sinus.</intervention_name>
    <description>Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.</description>
    <arm_group_label>Biventricular resynchronization therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must indicate their acceptance to participate in the study by signing an&#xD;
             informed consent document.&#xD;
&#xD;
          -  The patient must be ≥ 18 years of age.&#xD;
&#xD;
          -  Left bundle branch block, QRS ≥130 and FEVI &lt;=35% (Indication of cardiac&#xD;
             resynchronization IA or IB ESC Guidelines). No indication of stimulation for AV block.&#xD;
&#xD;
          -  Patients with indication of resynchronization therapy for ventricular dysfunction and&#xD;
             indication of cardiac stimulation for AV block according to ESC Guidelines (IA ESC&#xD;
             Guidelines).&#xD;
&#xD;
          -  Non-left bundle branch block, QRS ≥150 and FEVI &lt;=35% (Indication of cardiac&#xD;
             resynchronization IIaB ESC Guidelines).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction, unstable angina or cardiac revascularization during the&#xD;
             previous 3 months.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Participating currently in a clinical investigation that includes an active treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Tolosana, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margarida Pujol Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lluis Mont Girbau, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Select</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Josep Lluis Mont Girbau</investigator_full_name>
    <investigator_title>Head of Arrhythmia Section. Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Physiological pacing</keyword>
  <keyword>Resynchronization therapy</keyword>
  <keyword>Electrocardiographic imaging</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

